Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-based treatment for multiple sclerosis spasticity can now proceed. Volume of 2.14 million shares traded was 5.5 times the 65-day average of 385,930. GW Pharma GWPH, +2.41% is the first company to win U.S. Continue reading →

MS Ireland and Novartis have launched a new video series entitled SPMS Explained,which aims to support those living with secondary progressive multiple sclerosis (SPMS) in Ireland. People with SPMS are typically diagnosed after 10 to 20 years living with relapsing remitting MS (RRMS) and studies indicate that 50% of those diagnosed with RRMS will transition to SPMS within 10 years, and 90% will transition within 25 years. SPMS symptoms do not go away completely after a relapse or flare-up and there is a steady increase in disability Continue reading →

Not intended for UK and US based media -Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to 605 million in development and commercial milestones, plus royalties on any future net sales DARMSTADT, Germany, Nov. Continue reading →

This article was originally published here Brain Behav Immun. 2020 Nov 3:S0889-1591(20)32378-3. doi: 10.1016/j.bbi.2020.11.004. Continue reading →

This article was originally published here BMC Med. 2020 Nov 4;18(1):298. doi: 10.1186/s12916-020-01769-6. Continue reading →

What Is Pelvic Floor Physical Therapy? If youre having problems with bladder, bowel, or sexual function due to your MS, one option to consider is pelvic floor physical therapy. Continue reading →

November 09, 2020 16:15 ET | Source: TG Therapeutics, Inc. NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. Continue reading →

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 9, 2020-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights Continue reading →